GEN Exclusives

More »

GEN News Highlights

More »
Oct 29, 2009

Micromet Obtains $11.84M Up Front in Cancer R&D Deal with Sanofi-Aventis

  • Sanofi-aventis is paying Micromet €8 million (about $11.84 million) to develop an antibody against an antigen present at the surface of carcinoma cells. Micromet is eligible for development and regulatory milestones of up to €162 million ($239.77 million), sales-related milestones of up to €150 million ($221.98 million), and royalties on worldwide product sales.

    Micromet will use its BiTE technology, which develops antibodies that activate a patient's T cells to seek and destroy cancer cells. The firm is responsible for the discovery, research, and development of the BiTE antibody through the completion of Phase I trials under the supervision of a joint steering committee. Sanofi-aventis will then have full responsibility for further development and worldwide commercialization.

    “Micromet's BiTE antibodies represent a promising new approach to treating cancer,” remarks Marc Cluzel, evp R&D, sanofi-aventis. “We believe BiTE antibodies have the potential to significantly expand the treatment options that we can offer to cancer patients in the future.”

    Typically, antibodies cannot engage T cells because T cells lack the appropriate receptors for binding antibodies. BiTE antibodies have been shown to bind T cells to tumor cells, ultimately inducing a self-destruction process in the tumor cells. In the presence of BiTE antibodies, T cells have been demonstrated to serially eliminate tumor cells. Through the killing process, T cells start to proliferate, which leads to an increased number of T cells at the site of attack.

     



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?